{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:21:43Z","timestamp":1788315703927,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Long\u2010acting cabotegravir plus rilpivirine (CAB+RPV) offers an alternative to daily oral therapy, but real\u2010world data in East Asia remain scarce. This study aims to evaluate the impact of CAB+RPV in people with HIV in Japan, focusing on virological outcomes, treatment continuation and inflammatory markers, providing valuable insight into the use of injectable regimens in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre retrospective study analysed routinely collected data from eight HIV centres in Japan on people with HIV who initiated CAB+RPV before January 2024. Virological, renal, inflammatory and lipid outcomes were assessed using follow\u2010up laboratory data obtained through April 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 136 participants, over 95% maintained HIV RNA &lt;50 copies\/mL, and more than 75% sustained undetectable levels through 14\u2009months. No virological failures occurred. Seven participants (5.1%) discontinued treatment, mostly due to injection site reactions (ISRs). Serum creatinine and cystatin C significantly decreased overall, although a significant change in serum creatinine was not observed in the subgroup switching from a regimen that did not contain a renal tubular transport inhibitor. CD4 and CD8 cell counts declined (median changes: \u221232 cells\/\u03bcL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0047; \u221252 cells\/\u03bcL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), with no significant change in the CD4\/CD8 ratio or CRP. high\u2010density lipoprotein cholesterol (HDL\u2010c) increased significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005), while LDL\u2010c and the T\u2010chol\/HDL\u2010c ratio remained unchanged.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the first multicentre real\u2010world data on CAB+RPV in Japan, demonstrating high virological outcomes among a significant portion of Japanese people with HIV. The findings suggest that CAB+RPV maintains a favourable safety profile, with no significant effects on chronic inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70096","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T10:09:13Z","timestamp":1754734153000},"page":"1673-1683","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-873X","authenticated-orcid":false,"given":"Eisuke","family":"Adachi","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Applied Immunology IMSUT Hospital of The Institute of Medical Science, The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5847-4108","authenticated-orcid":false,"given":"Rumi","family":"Minami","sequence":"additional","affiliation":[{"name":"Internal Medicine, Clinical Research Institute, NHO Kyushu Medical Center  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Shirano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Osaka City General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7686-4604","authenticated-orcid":false,"given":"Hideta","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Infectious, Respiratory, and Digestive Medicine, First Department of International Medicine University of the Ryukyus Graduate School of Medicine  Okinawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-6879","authenticated-orcid":false,"given":"Kazuaki","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-4106","authenticated-orcid":false,"given":"Mayumi","family":"Imahashi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases NHO Nagoya Medical Center  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Sekiya","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-4243","authenticated-orcid":false,"given":"Yusuke","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Teikyo University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7732-9870","authenticated-orcid":false,"given":"Toshibumi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Chiba University Hospital  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"J\u2010HIV RWD Collaborative Database Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad020"},{"key":"e_1_2_10_3_1","unstructured":"RamgopalMN BerniA CazanaveC et al.SOLAR 12\u2010month results: randomized switch trial of CAB+RPV LA VS ORAL B\/FTC\/TAF. The Conference on Retroviruses and Opportunistic Infections 2023 Seatle USA.2023."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010024\u201004490\u20100"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010024\u201009904\u2010x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103018(20)30340\u20104"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/m23\u20100788"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)32666\u20100"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103018(17)30068\u20101"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2023.0108"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad705"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.09.008"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid3008.240019"},{"key":"e_1_2_10_14_1","unstructured":"The 37th Annual Meeting of the Japanese Society for AIDS Research. Program and Abstracts. Kyoto Japan.2023."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121\u2010023\u201000890\u20102"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13679"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16030405"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/23259582221140208"},{"key":"e_1_2_10_21_1","unstructured":"ViiV Healthcare.Global Data Sheet for Cabotegravir (PrEP). Version 01. July 1 2021."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981\u2010023\u201000590\u20104"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx262"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu132"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.001"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2019.04.001"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27543"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29021"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2022.0115"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe078029"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:12:11Z","timestamp":1768194731000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/hiv.70096"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70096","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"2025-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}